➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Mallinckrodt
Colorcon
Boehringer Ingelheim
Johnson and Johnson

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

Patent: 10,016,440

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,016,440
Title:Methods of enhancing antibody-dependent cellular cytotoxicity
Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
Inventor(s): Hershberg; Robert (Seattle, WA)
Assignee: VentiRx Pharmaceuticals, Inc. (Seattle, WA)
Application Number:13/092,088
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,016,440
Patent Claims:see list of patent claims

Details for Patent 10,016,440

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28 ⤷  Free Forever Trial VentiRx Pharmaceuticals, Inc. (Seattle, WA) 2030-04-21 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22 ⤷  Free Forever Trial VentiRx Pharmaceuticals, Inc. (Seattle, WA) 2030-04-21 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22 ⤷  Free Forever Trial VentiRx Pharmaceuticals, Inc. (Seattle, WA) 2030-04-21 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27 ⤷  Free Forever Trial VentiRx Pharmaceuticals, Inc. (Seattle, WA) 2030-04-21 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27 ⤷  Free Forever Trial VentiRx Pharmaceuticals, Inc. (Seattle, WA) 2030-04-21 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27 ⤷  Free Forever Trial VentiRx Pharmaceuticals, Inc. (Seattle, WA) 2030-04-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,016,440

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2011133819 ⤷  Free Forever Trial
United States of America 2012003213 ⤷  Free Forever Trial
United States of America 2013236449 ⤷  Free Forever Trial
United States of America 2017027954 ⤷  Free Forever Trial
Russian Federation 2012149452 ⤷  Free Forever Trial
Russian Federation 2627660 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Moodys
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.